Systems-Level Changes to Address Financial Toxicity in Cancer Care
- 1 April 2022
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (4) , 310-311
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom ReliefJCO Oncology Practice, 2021
- Compliance With Price Transparency Rules at US National Cancer Institute–Designated Cancer CentersJAMA Oncology, 2021
- Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging ProblemJCO Oncology Practice, 2021
- Financial Burden of Drugs Prescribed for Cancer-Associated SymptomsJCO Oncology Practice, 2021
- Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization’s Response for Readiness, Mitigation, and ResilienceJCO Oncology Practice, 2021
- Financial Toxicity and Cancer Care #409Journal of Palliative Medicine, 2021
- Patient Perspectives on the Financial Costs and Burdens of Breast Cancer SurgeryJCO Oncology Practice, 2021
- Real-Time Benefit Tools for Drug PricesJAMA, 2019